24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
Pregnant Women Need to Guard Against CoronavirusCollege Students Feeling the Strain of Social DistancingHow One Patient's Battle With COVID-19 Changed U.S. Testing ProtocolsMission Possible: Tips for Safe Grocery Shopping During the PandemicTrials Begin for Potential COVID-19 Drug RemdesivirSchool Closures Will Force Many U.S. Health Care Workers to Stay HomeWith Coronavirus a Threat, Stop Wearing Contact LensesSome Steroid Meds May Raise Coronavirus RiskAmericans Got the Memo on Social Distancing, Poll ShowsCDC Urges All Americans to Wear Face Masks as Death Count RisesAHA News: Amid Coronavirus Crisis, Exercise Caution When Exercising OutdoorsAsthma, COPD Raise Odds for Severe COVID-19, Lung Experts WarnCoronavirus Hangs Around Even After Symptoms SubsideCan Food From an Infected Cook Give You COVID-19?Pregnant Women Need to Guard Against CoronavirusVitamin D Might Aid Seniors' Recovery From Hip Fracture: StudyWith 3D Printer, N.Y. Hospital Converts Sleep Apnea Machines Into VentilatorsAnother COVID-19 Vaccine Being Tested in Mice'Stay at Home' Orders Are Stressing U.S. Families, Survey ShowsAn Expert's Guide to Fighting Coronavirus StressHeart Patients Need to Be Wary of CoronavirusU.S. Coronavirus Cases Pass 200,000, as Jobless Claims Soar to 10 MillionIs Thyroid Hormone Dangerously Overprescribed in Older Patients?'Pink Eye' Often a Symptom of COVID-19, and Infection Via Tears PossibleMild COVID-19 Often Appears With Only Gastro Symptoms: StudyFDA Pulls Heartburn Drug Zantac From MarketCertain Health Conditions Up Risks for Severe COVID-19Parents, Arm Your Kids Against COVID-19 With Good Hand-Washing HabitsFDA Approves Malaria Drugs to Treat COVID-19, Despite Little Proof They Work'Fever Tracker' Suggests Social Distancing Is Already WorkingDon't Fall Prey to COVID-19 ScammersBeing Chained to Your Desk Might Harm Your ThyroidWhat You Should Know If Your Surgery Has Been Put on HoldAnother Coronavirus Health Threat: Too Few Asthma InhalersOdds of Hospitalization, Death With COVID-19 Rise Steadily With Age: StudyAHA News: Health Emergency? Don't Hesitate to Get HelpToo Many Patients, Too Few Ventilators: How U.S. Hospitals Cope With COVID-19AI Might Spot Which COVID-19 Patients Are at Risk of Severe DiseaseWhat Dental Offices Are Doing to Prevent Coronavirus Infection?A Parent's Guide to Fighting Coronavirus StressTrump Extends Social Distancing to April 30 as COVID-19 Cases SurgeRecovery From Mild Brain Trauma Takes Longer Than Expected: StudyStaying at Home During the Pandemic? Use Technology to Stay ConnectedAHA News: Understanding the Basics of 'Herd Immunity'Multiple Measures of Social Distancing Required to Slow Coronavirus: StudyCough, Fever, Fatigue? Head to CDC's Online Coronavirus Symptom CheckerThree Countries Have Kept Coronavirus in Check; Here's How They Did ItTrial Finds Acupuncture May Help Prevent MigrainesSevere COVID-19 Might Injure the HeartWhy Are Teens, Millennials Ignoring Coronavirus Warnings?
Questions and AnswersLinks
Related Topics

Diabetes

New Drug Helps Shrink Inoperable Tumors in Kids

HealthDay News
by -- Steven Reinberg
Updated: Mar 20th 2020

new article illustration

FRIDAY, March 20, 2020 (HealthDay News) -- A new trial confirms that the drug selumetinib shrinks tumors in children suffering from neurofibromatosis type 1.

The condition is characterized by changes in skin coloring and the growth of tumors along nerves in the skin, brain and other parts of the body. The tumors cause disfigurement, limitations on strength and range of motion, and pain.

The tumors are hard to treat, and they can grow quickly and become up to 20% of a child's weight, the study authors noted.

Surgery is often not an option because the tumors intertwine with healthy nerves and tissue. Even ones that are partially removed tend to grow back, especially in young children.

In the study, children given selumetinib experienced less pain, improved function and overall better quality of life, the researchers reported.

"Until now, no effective medical therapies have existed for children with neurofibromatosis type 1 [NF1] and plexiform neurofibromas, and it's been a long journey to find a drug that can help them," said researcher Dr. Brigitte Widemann. She's chief of the Center for Cancer Research's Pediatric Oncology Branch at the U.S. National Institutes of Health (NIH).

"While this is not yet a cure, this treatment is shrinking tumors and it's making children feel better and have a better quality of life," she said in an NIH news release.

The trial included 50 children, aged 3 to 17, with NF1-related plexiform neurofibromas in 2015 and 2016.

The children were given selumetinib twice a day in 28-day cycles and assessed at least every four cycles.

By March 2019, 70% of the children had a partial response, which was a reduction in the size of the tumors of 20% or more. That response lasted a year or more.

After a year of treatment, children and parents reported less pain and meaningful improvement in daily function, overall quality of life, strength and range of motion, the researchers found.

According to Dr. Andrea Gross, also from the Center for Cancer Research, "One of the most surprising findings of this trial was the impact the treatment had on pain. It even helped patients who had been living with chronic, debilitating pain come off pain medications, which was not something we anticipated. So, that was a really exciting finding."

Five children stopped selumetinib because of possible side effects from the drug, and the disease progressed in six. The most common side effects were nausea and vomiting, diarrhea and rashes, the researchers said.

Widemann pointed out that "there's a lot more to be done. Even though these children have tumor shrinkage, many still have disabling tumors. But these findings are a big step forward and inspire us to work even harder towards additional progress in NF1 therapies."

The report was published March 18 in the New England Journal of Medicine.

More information

For more on NF1, head to the U.S. National Institutes of Health.